J&J files suit against Amgen to protect Procrit sales

Share this article:
Johnson & Johnson has filed an antitrust lawsuit accusing rival Amgen of engaging in illegal sales practices to drive its best-selling drug Procrit (epoetin alfa) out of the market.
The lawsuit was filed in Federal District Court in Trenton, N.J.
"We believe the allegations in the complaint are without merit, and we plan to vigorously defend our position," Mary Klem, Amgen associate director, external communications, told MM&M.
The dispute involves Amgen's anti-anemia drug, Aranesp (darbepoetin alfa), which J&J's Ortho Biotech said now accounts for about two-thirds of sales to oncology clinics for products to aid red-blood cell growth.
Ortho Biotech claimed in the suit that Amgen penalizes oncology clinics by requiring they buy nearly all red blood-cell growth drugs from Amgen if the clinics want good deals on its two white blood-cell growth drugs, Neulasta (pegfilgrastim) and Neupogen (filgrastim).
Amgen has a near monopoly for the lifesaving white blood cell drugs, with 98 percent of clinic sales, Ortho Biotech said.
Failure to buy at least 75 percent of red blood cell growth drugs from Amgen means that a clinic will have to buy Neulasta and Neupogen at prices that exceed government reimbursement, the lawsuit said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...